Macrophages exist in various tissues, several body cavities, and around mucosal surfaces
and are a vital part of the innate immune system for host defense against many pathogens …

Owing to the dysregulation of protein kinase activity in many diseases including cancer, this
enzyme family has become one of the most important drug targets in the 21 st century. There …

The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer
therapy and heralded the emergence of kinase inhibitors as a key drug class in the oncology …

Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …

The central role of dysregulated kinase activity in the etiology of progressive disorders,
including cancer, has fostered incremental efforts on drug discovery programs over the past …

Biomarkers-guided precision therapeutics has revolutionized the clinical development and
administration of molecular-targeted anticancer agents. Tailored precision cancer therapy …

Abstract N6-methyladenosine (m6A) has emerged as an abundant modification throughout
the transcriptome with widespread functions in protein-coding and noncoding RNAs. It …

Owing to the dysregulation of protein kinase activity in many diseases including cancer, the
protein kinase enzyme family has become one of the most important drug targets in the 21st …

Targeting the EGFR with small-molecule inhibitors is a confirmed valid strategy in cancer
therapy. Since the FDA approval of the first EGFR-TKI, erlotinib, great efforts have been …

Owing to the dysregulation of protein kinase activity in many diseases including cancer, this
enzyme family has become one of the most important drug targets in the 21 st century. There …